Share on StockTwits

A number of stock research firms have changed their ratings and price targets for Pharmacyclics (NASDAQ: PCYC) during the last seven days:

  • Pharmacyclics had its “buy” rating reaffirmed by analysts at Roth Capital.
  • Pharmacyclics was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $142.00 price target on the stock, up previously from $102.00.
  • Pharmacyclics had its “buy” rating reaffirmed by analysts at Nomura. They now have a $177.00 price target on the stock, up previously from $174.00.
  • Pharmacyclics had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $152.00 price target on the stock, up previously from $150.00.
  • Pharmacyclics had its price target raised by analysts at Morgan Stanley from $94.00 to $101.00.
  • Pharmacyclics had its price target raised by analysts at Credit Suisse from $121.00 to $163.00.
  • Pharmacyclics had its price target raised by analysts at RBC Capital from $95.00 to $100.00.
  • Pharmacyclics had its “buy” rating reaffirmed by analysts at Deutsche Bank. They now have a $180.00 price target on the stock.
  • Pharmacyclics had its price target raised by analysts at JMP Securities from $191.00 to $200.00. They now have a “market outperform” rating on the stock.
  • Pharmacyclics had its “neutral” rating reaffirmed by analysts at Zacks. They now have a $126.00 price target on the stock. Zacks‘ analyst wrote, “Pharmacyclics’ second quarter 2014 loss (including stock-based compensation expenses) of $0.49 per share was wider than the Zacks Consensus Estimate of a loss of $0.20. Moreover, loss in the second quarter of 2014 compared unfavorably with the year-ago earnings of $0.17 per share. Earnings in the quarter were hurt by higher expenses. Total revenues of $113 million in the second quarter of 2014 were well above the Zacks Consensus Estimate of $90 million. Revenues in the quarter included Imbruvica sales of $109.5 million. We believe that the stock is fairly valued at current levels and hence maintain our Neutral recommendation on the stock. Our target price is $126.00 per share.”
  • Pharmacyclics was upgraded by analysts at WallachBeth Capital from a “hold” rating to a “buy” rating. They now have a $160.00 price target on the stock.
  • Pharmacyclics had its price target raised by analysts at William Blair from $150.00 to $180.00. They now have an “outperform” rating on the stock.

Shares of Pharmacyclics, Inc. (NASDAQ:PCYC) opened at 119.83 on Wednesday. Pharmacyclics, Inc. has a 1-year low of $82.51 and a 1-year high of $154.89. The stock’s 50-day moving average is $98.91 and its 200-day moving average is $108.7. The company has a market cap of $9.004 billion and a price-to-earnings ratio of 106.40.

Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.

Receive News & Ratings for Pharmacyclics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.